Ouro’s series A was co-led by TPG Life Sciences Innovations, NEA and Norwest Venture Partners. Monograph Capital participated in the round and also founded the company in partnership with GSK ...

Ouro Medicines’ name is short for ouroboros, an ancient symbol of a snake eating itself for eternal recycling, rebirth and renewal. A San Francisco startup, founded by Big Pharma player GSK plc ...

On Friday, San Francisco-based Ouro emerged from stealth revealing $120 million in funding from backers that include GSK, which helped form the young company. “Fundamentally, we think this could ...

Starting later this year, Ouro intends to start a phase 1 clinical ... with participation from Monograph, GSK, UPMC Enterprises, Boyu/Zoo Capital, LongRiver Investments, and other unnamed investors.

Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also backed by leading investors TPG, NEA, and Norwest. For more information ...

B cells, like those pictured above, malfunction in autoimmune diseases and are the target of a number of CAR-T therapies in clinical testing.

California-based immunology start-up Ouro Medicines, which is developing immune reset therapeutics for people living with chronic immune-mediated diseases, has announced its launch with $120 million ...

SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company ... The company was founded by Monograph Capital in partnership with GSK plc. The Series A was co-led by ...